Advertisement
Clinical Research and Public HealthImmunologyOncology
Open Access | 
10.1172/JCI179501
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Brad H. Nelson,1,2,3 Phineas Hamilton,1 Minh Tung Phung,4,5 Katy Milne,1 Bronwyn Harris,1 Shelby Thornton,1 Donald Stevens,1 Shreena Kalaria,1,2 Karanvir Singh,1 Céline M. Laumont,1,3 Elena Moss,1 Aliya Alimujiang,4 Nicola S. Meagher,6,7 Adelyn Bolithon,6,8 Sian Fereday,9,10 Catherine J. Kennedy,11,12,13 Joy Hendley,9 Dinuka Ariyaratne,9 Kathryn Alsop,9,10 Nadia Traficante,9,11 Ellen L. Goode,14 Anthony Karnezis,15 Hui Shen,16 Jean Richardson,17,18 Cindy McKinnonDeurloo,18 Anne Chase,18 Bronwyn Grout,18 Jennifer Anne Doherty,19 Holly R. Harris,20,21 Kara L. Cushing-Haugen,20 Michael Anglesio,22,23 Karolin Heinze,22,23 David Huntsman,22,24 Aline Talhouk,22,23 Gillian E. Hanley,22,23 Jennifer Alsop,25 Mercedes Jimenez-Linan,26 Paul D.P. Pharoah,27 Jessica Boros,11,12,13 Alison H. Brand,12,13 Paul R. Harnett,13,28 Raghwa Sharma,13,29,30 Jonathan L. Hecht,31 Naoko Sasamoto,32 Kathryn L. Terry,32,33 Beth Karlan,34 Jenny Lester,34 Michael E. Carney,35 Marc T. Goodman,36 Brenda Y. Hernandez,37 Lynne R. Wilkens,37 Sabine Behrens,38 Renée Turzanski Fortner,38,39 Peter A. Fasching,40 Christiani Bisinotto,41 Francisco José Candido dos Reis,41 Prafull Ghatage,42 Martin Köbel,43 Esther Elishaev,44 Francesmary Modugno,45,46,47 Linda Cook,48,49 Nhu Le,50 Aleksandra Gentry-Maharaj,51,52 Usha Menon,51 María J. García,53 Cristina Rodriguez-Antona,54,55 Kyo Farrington,43 Linda E. Kelemen,56 Stefan Kommoss,57 Annette Staebler,58 Dale W. Garsed,9,10 James D. Brenton,59 Anna M. Piskorz,59 David D.L. Bowtell,9,10 Anna DeFazio,7,11,12,13 Susan J. Ramus,6,8 Malcolm C. Pike,60 and Celeste Leigh Pearce4
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Nelson, B. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Hamilton, P. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Phung, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Milne, K. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Harris, B. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Thornton, S. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Stevens, D. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Kalaria, S. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Singh, K. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Laumont, C. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Moss, E. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Alimujiang, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Meagher, N. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Bolithon, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Fereday, S. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Kennedy, C. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Hendley, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Ariyaratne, D. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Alsop, K. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Traficante, N. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Goode, E. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Karnezis, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Shen, H. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Richardson, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by McKinnonDeurloo, C. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Chase, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Grout, B. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Doherty, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Harris, H. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Cushing-Haugen, K. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Anglesio, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Heinze, K. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Huntsman, D. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Talhouk, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Hanley, G. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Alsop, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Jimenez-Linan, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Pharoah, P. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Boros, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Brand, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Harnett, P. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Sharma, R. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Hecht, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Sasamoto, N. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Terry, K. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Karlan, B. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Lester, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Carney, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Goodman, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Hernandez, B. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Wilkens, L. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Behrens, S. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Turzanski Fortner, R. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Fasching, P. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Bisinotto, C. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Candido dos Reis, F. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Ghatage, P. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Köbel, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Elishaev, E. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Modugno, F. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Cook, L. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Le, N. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Gentry-Maharaj, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Menon, U. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by García, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by
Rodriguez-Antona, C.
in:
JCI
|
PubMed
|
Google Scholar
|
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Farrington, K. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Kelemen, L. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Kommoss, S. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Staebler, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by
Garsed, D.
in:
JCI
|
PubMed
|
Google Scholar
|
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Brenton, J. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Piskorz, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Bowtell, D. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by DeFazio, A. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Ramus, S. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Pike, M. in: JCI | PubMed | Google Scholar
1Deeley Research Centre, BC Cancer, Victoria, British Columbia, Canada.
2Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada.
3Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.
4School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
5Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
6School of Clinical Medicine, University of New South Wales (NSW) Medicine and Health, University of NSW Sydney, Sydney, New South Wales, Australia.
7The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
8Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, New South Wales, Australia.
9Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
10Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
11Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, New South Wales, Australia.
12Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia.
13Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
14Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
15Department of Pathology, University of California Davis School of Medicine, Sacramento, California, USA.
16Van Andel Institute, Grand Rapids, Michigan, USA.
17Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
18Patient advocate.
19Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA.
20Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
21Department of Epidemiology, University of Washington, Seattle, Washington, USA.
22Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada.
23British Columbia’s Gynecological Cancer Research Team (OVCARE), University of British Columbia, BC Cancer, and Vancouver General Hospital, Vancouver, British Columbia, Canada.
24Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, British Columbia, Canada.
25Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
26Department of Histopathology, Addenbrooke’s Hospital, Cambridge, United Kingdom.
27Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, California, USA.
28Crown Princess Mary Cancer Centre and
29Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Westmead Hospital, Sydney, New South Wales, Australia.
30Western Sydney University, Sydney, New South Wales, Australia.
31Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
32Obstetrics and Gynecology Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.
33Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
34David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, California, USA.
35Department of Obstetrics and Gynecology, John A. Burns School of Medicine University of Hawaii, Honolulu, Hawaii, USA.
36Cancer Prevention and Control Program, Cedars-Sinai Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.
37University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
38Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
39Department of Research, Cancer Registry of Norway, Oslo, Norway.
40Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
41Department of Gynecology and Obstetrics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
42Department of Oncology, Division of Gynecologic Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
43Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada.
44Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
45Department of Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, USA.
46Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
47Women’s Cancer Research Center, Magee-Womens Research Institute and Hillman Cancer Center, Pittsburgh, Pennsylvania, USA.
48Epidemiology, School of Public Health, University of Colorado, Aurora, Colorado, USA.
49Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
50Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada.
51MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology and
52Department of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, University College London, London, United Kingdom.
53Cancer Biology Department, Sols-Morreale Biomedical Research Institute (IIBM), CSIC UAM, Madrid, Spain.
54Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
55Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.
56Division of Acute Disease Epidemiology, South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA.
57Department of Women’s Health and
58Institute of Pathology and Neuropathology, Tuebingen University Hospital, Tuebingen, Germany.
59Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom.
60Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Address correspondence to: Brad H. Nelson, Deeley Research Centre, BC Cancer, 2410 Lee Avenue, Victoria, British Columbia, V8R 6V5, Canada. Phone: 250.519.5700; Email: bnelson@bccrc.ca. Or to: Celeste Leigh Pearce, University of Michigan, School of Public Health 1415, Washington Heights, Ann Arbor, Michigan 48109, USA. Phone: 734.764.3835; Email: lpearce@umich.edu.
Authorship note: PH and MTP contributed equally to this work.
Find articles by Pearce, C. in: JCI | PubMed | Google Scholar
Published October 29, 2024 - More info
J Clin Invest. 2024;134(24):e179501. https://doi.org/10.1172/JCI179501.
© 2024 Nelson et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Received: January 31, 2024; Accepted: October 9, 2024
Related article:
Abstract
The approach and efficacy of treatments for high-grade serous carcinoma (HGSC) of the ovary have changed little in decades. Although numerous studies demonstrated immune infiltration as frequent and prognostically beneficial, clinical trials of immunotherapies have generated benefit in fewer than 15% of patients. In this issue of the JCI, Nelson and colleagues compiled 1,233 HGSC samples from patients across four continents and compared the molecular and immunologic features that associate with long-term survival (greater than 10 years). Diversity among HGSC tumors is well defined, but this study explored the combined influence of immunologic and molecular features. Long-term survivors harbored tumors with high epithelial content and overrepresentation of the C4/differentiated molecular signature, with cytotoxic T and B cells infiltrating to the tumor epithelium and stroma, respectively. These findings highlight features that might underly poor responsiveness to existing immunotherapies of most HGSC tumors and considerations for the design of future, more precise treatments for HGSC.
Authors
Jeanette E. Boudreau
-
Results
Diverse immune-cell subsets are associated with long-term survival. Table 1 and Supplemental Table 1 (Supplemental Material available online with this article; https://doi.org/10.1172/JCI179501DS1) summarize key features of the 1,223 evaluated participants (374 LTS, 433 MTS, 416 STS). Multi-color IHC or immunofluorescence (IF) was used to determine the densities of 10 immune-cell subsets in the epithelial and stromal regions of the tumors; an 11th immune-cell subset was generated by summing CD8+FoxP3– and CD8+FoxP3+ T cell counts to create a single “CD8+ T cell” measure (Table 2). Immune cells were generally more abundant in stromal than epithelial tumor regions. Most immune-cell subsets were positively correlated (Figure 1), the only exception being CD68+PD-L1– TAMs, which showed no association with other immune-cell types.
Figure 1Heatmap showing pairwise Spearman correlations between immune cell subsets. The color scale indicates the strength of the correlation between densities with red indicating high positive correlation. Epi, intraepithelial location; Str, intrastromal location of immune cells.
In HGSC and other cancers, an “immune excluded” TIL pattern has been described in which T cells are predominantly restricted to tumor stroma rather than epithelium (34). To assess this, we plotted intraepithelial versus intrastromal CD8+ T cell densities (Figure 2). Although a small number of tumors were devoid of intraepithelial CD8+ cells or intrastromal CD8+ cells (which was likely attributable to the small size of the tissue microarray [TMA] cores), we found no evidence of a distinct subgroup of tumors with substantial intrastromal values and negligible intraepithelial values overall or individually for the LTS, MTS, and STS groups (Figure 2). Thus, immune exclusion was not evident in our cohort, and we did not consider this or other spatial patterns in subsequent analyses.
Figure 2Intrastromal versus intraepithelial CD8+ TIL densities (cells/mm2) in tumors from all participants and from the STS, MTS, and LTS subgroups. The relationship of the intrastromal CD8+ density values to the intraepithelial CD8+ density values showed no differences between STS and LTS (P = 0.60).
Table 3 shows the ORs (using D0.25; see Methods and Statistics) comparing LTS to STS, LTS to MTS, and MTS to STS for all immune-cell subsets in epithelium and in stroma. In the LTS to STS comparison, with the exception of CD68+PD-L1– TAMs, all immune-cell subsets were substantially more abundant in LTS than STS in the epithelium and/or stroma. Within the epithelial compartment, we found highly statistically significant associations with survival for intraepithelial CD8+ T cells (including both FoxP3– and FoxP3+ subsets), PD-1+ immune cells, CD68–PD-L1+ cells (presumptive PD-L1+ tumor cells), and B cells. Within the stromal compartment, the most significant associations (P ≤ 0.002) were seen for CD8+FoxP3+ T cells, PD-1+ cells, CD20–CD79+ plasma cells, and CD68–PD-L1+ cells. Intra-epithelial CD8+FoxP3+ T cells and PD-1+ cells had the strongest associations based on OR magnitude. Most immune marker associations for MTS versus STS were substantially weaker than those for LTS versus STS (Table 3). Results restricted to participants whose samples were known to be adnexal (data not shown) or who were known to have received primary cytoreductive surgery (PCS) (Supplemental Table 2) were not materially different from our main results (data not shown).
Prognostic effects of TILs are strongest in tumors with high epithelial content. To investigate whether epithelial-to-stromal content influenced the magnitude or prognostic significance of immune-cell infiltrates, patients were stratified into epithelium-high versus -low groups (see Supplemental Methods and Statistics). Epithelial content showed no significant association with LTS, MTS, or STS groups. The densities of almost all immune-cell subsets (both intraepithelial and intrastromal) were higher in the epithelium-low group, with the exception of intraepithelial CD68+PD-L1+ TAMs and intra-epithelial and intrastromal CD68+PD-L1– TAMs (Table 2). For example, Figure 3 compares the densities of CD8+FoxP3– T cells and PD-1+ cells in epithelium-high versus epithelium-low tumors.
Figure 3Violin plots comparing the densities of immune cell subsets in epithelium-high versus –low tumors. (A) Density of intraepithelial CD8+FoxP3– T cells in all tumors, epithelium-low tumors, and epithelium-high tumors. (B) Intrastromal CD8+FoxP3– T cells. (C) Intraepithelial PD-1+ immune cells. (D) Intrastromal PD-1+ immune cells. Embedded box plots indicate median (horizontal line), quartile (box edges), and outliers (points).
We next evaluated the impact of epithelial content on the prognostic effects of immune markers. Table 4, Figure 4, and Supplemental Figure 1 show a comparison of the LTS and STS groups. Immune marker associations were markedly stronger in the epithelium-high group compared with the epithelium-low group. In the epithelium-high group, 9 of 11 intraepithelial (Table 4, Figure 4) and 10 of 11 intrastromal (Supplemental Figure 1) immune-cell subsets showed a statistically significant association with survival groups (LTS versus STS); this included all T cell, B cell, and plasma cell subsets. By contrast, in the epithelium-low group, only intraepithelial CD8+ T cells and PD-1+ cells were statistically significantly associated with survival group. Thus, the association of TILs with LTS was largely restricted to tumors with high epithelial content, even though TIL densities were generally higher in epithelium-low tumors (Figure 3). Similar results were obtained when quartile (see Methods section, Statistics) OR results were used to compare LTS to STS by epithelium group (Supplemental Table 3). In the MTS versus STS comparison, the influence of epithelial content was evident but less striking (Supplemental Table 4).
Figure 4Forest plot of the odds ratios and 95% CIs of LTS compared with STS for intraepithelial immune cell subsets stratified by epithelium-high versus epithelium-low tumors.
Table 4D0.25 odds ratios of immune-cell subsets comparing long-term survivors to short-term survivors by epithelium group
Further analyses of immune-cell subsets were performed in 2 population-based HGSC cohorts: Canadian Ovarian Experimental Unified Resource (COEUR) (n = 981) (35) and Ovarian Outcomes Unit (OOU) (n = 192) (36); the latter had previously been stained to detect T cell phenotypes (including CD39+ and CD103+ T cells) that were not evaluated in the MOCOG or COEUR panels. Similar to the MOCOG findings, these analyses showed that the prognostic effects of most TIL subsets were restricted to epithelium-high tumors, despite immune-cell densities being generally higher in epithelium-low tumors (Supplemental Material and Supplemental Tables 5–8).
Intrastromal B cells complement the prognostic effect of intraepithelial CD8+ T cells. We investigated which combination of immune cells best predicted outcome in the epithelium-high group. Because of the well-accepted importance of intraepithelial CD8+ T cells, we included this marker in the analysis a priori. After accounting for intraepithelial CD8+ T cells, intrastromal B cells were the only other immune-cell subset that distinguished LTS and STS (Supplemental Table 9). PD-1+ immune cells and CD8+ T cell densities were highly correlated, and interchanging PD-1+ and CD8+ left the conclusions unchanged. In a joint effects model (Table 5), an OR of 4.87 was observed for the highest quartile for intraepithelial CD8+ T cells and nonzero for intrastromal B cells (P < 0.001, with no statistical interaction between these 2 markers [P > 0.05]).
Table 5Odds ratios for the joint effects of intraepithelial CD8+ T cells and intrastromal B cells for long-term survivors compared with short-term survivors in the epithelium-high group
The prognostic effects of immune cells depend on molecular subtype. Molecular subtyping data was available for 217 LTS, 251 MTS, and 226 STS MOCOG cases (33). Across all 3 groups combined, the molecular subtypes were distributed as: C1/MES (24%), C2/IMM (27%), C4/DIF (33%), and C5/PRO (16%). There was no statistically significant association between molecular subtype and survival group. Consistent with prior reports (33, 37), epithelial content was highest in the C4/DIF subtype (median, 75%), lowest in the C1/MES subtype (median, 57%), and intermediate in the C2/IMM (median, 67%) and C5/PRO subtypes (median, 69%), (P < 0.001).
As expected, the C2/IMM subtype had the highest median densities of all intraepithelial and intrastromal immune-cell subsets, followed in order by the C1/MES, C4/DIF, and C5/PRO subtypes (Table 6 and Figure 5). For most immune-cell subsets, the ratio of intrastromal to intraepithelial cell densities did not vary substantially between molecular subtypes.
Figure 5Multiplex IF images showing CD8+ and FoxP3+ TILs in epithelium-high versus -low tumors. Images further stratified by molecular subtype (C1/MES, C2/IMM and C4/DIF); 2 representative examples of each subgroup are shown. Tumor cells are highlighted by pan-cytokeratin staining (light gray). DAPI staining (blue) detects all cell nuclei. Scale bars: 100 μm. Red, CD8+; green, FoxP3+.
Unexpectedly, the association between immune cells and LTS was near exclusive (with only 1 exception) to the C4/DIF subtype. Statistically significant positive associations were seen for 5 of 11 intraepithelial and 4 of 11 intrastromal cell subsets (Table 7, Figure 6, and Supplemental Figure 2), despite the fact that C4/DIF tumors ranked third among the molecular subtypes with respect to the densities of 19 of 22 immune-cell subsets (Table 6). In contrast, the C2/IMM molecular subtype had the highest median levels of all intraepithelial and intrastromal immune-cell subsets (Table 6), yet only intraepithelial CD8+FoxP3+ T cells showed a statistically significant association with LTS within this molecular subtype (Table 7).
Figure 6Forest plot of the odds ratios and 95% CIs of LTS compared with STS of intraepithelial immune-cell subsets for the C1/MES, C2/IMM, and C4/DIF molecular subtypes in epithelium-high cases. Plasma cell results for the C1/MES subtype could not be calculated. The C5/PRO subtype is not presented as several could not be calculated. *P < 0.05 for heterogeneity across subtypes.
Table 7D0.25 odds ratios of immune-cell subsets comparing long-term survivors with short-term survivors by PrOTYPE
To investigate whether these C4/DIF results reflected the influence of tumor epithelium, we restricted the comparison between LTS and STS to epithelium-high tumors (Table 8). As expected (33, 37), a higher proportion of C4/DIF tumors were epithelium-high (n = 104 of 155, 67%) compared with C1/MES (n = 31 of 109, 28%), C2/IMM (n = 61 of 108, 56%), and C5/PRO tumors (n = 33 of 71, 46%) (Tables 7 and 8). Strikingly, within epithelium-high tumors, the prognostic significance of immune cells was exclusive to the C4/DIF subtype, with 8 of 11 intraepithelial and 6 of 11 intrastromal subsets showing a statistically significant association with LTS. There were no statistically significant associations within the other molecular subtypes (Table 8).
Table 8D0.25 odds ratios of immune-cell subsets comparing epithelium-high long-term suvivors to short-term survivors by PrOTYPE
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)